BDSI BioDelivery Sciences International Inc.

3.55
-0.14  -4%
Previous Close 3.69
Open 3.65
Price To Book 7.1
Market Cap 250955244
Shares 70,691,618
Volume 482,568
Short Ratio
Av. Daily Volume 680,769

NewsSee all news

  1. Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
  2. Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors
  3. BioDelivery (BDSI) Down 1.6% Since Last Earnings Report: Can It Rebound?
  4. Edited Transcript of BDSI earnings conference call or presentation 8-Nov-18 9:30pm GMT
  5. BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up

SEC filingsSee all SEC filings

  1. S-3 - Registration statement under Securities Act of 1933 181171474
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170465
  3. 8-K - Current report 181169867
  4. 8-K - Current report 181144811
  5. 8-K - Current report 181071731

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
  2. Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors
  3. BioDelivery (BDSI) Down 1.6% Since Last Earnings Report: Can It Rebound?
  4. Edited Transcript of BDSI earnings conference call or presentation 8-Nov-18 9:30pm GMT
  5. BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
  6. Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International — Fundamental Analysis, Key Performance Indications
  7. BioDelivery Sciences International (BDSI) Reports Q3 Loss, Misses Revenue Estimates
  8. BioDelivery: 3Q Earnings Snapshot
  9. BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
  10. The most valuable public companies in the Triangle (Slideshow)
  11. 5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
  12. BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
  13. BioDelivery Sciences International (BDSI) Expected to Beat Earnings Estimates: Should You Buy?
  14. Penny Stocks to Buy Using Technical Analysis for November 2018
  15. BioDelivery Sciences Announces Changes to its Executive Leadership Team
  16. New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives and Sustained Production
  17. Can The Uptrend Continue for BioDelivery Sciences International (BDSI)?
  18. From Iqvia's Bousbib to Red Hat's Whitehurst: Who made the most from inside stock sales in 3Q2018
  19. Who Are The Major Shareholders Of BioDelivery Sciences International Inc (NASDAQ:BDSI)?

SEC Filings

  1. S-3 - Registration statement under Securities Act of 1933 181171474
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170465
  3. 8-K - Current report 181169867
  4. 8-K - Current report 181144811
  5. 8-K - Current report 181071731
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 181023754
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181006179
  8. 8-K - Current report 181005211
  9. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181002360
  10. 8-K - Current report 18995135